This site is intended for a healthcare professional audience in the United States.

Contact the distributors below to order GIAPREZA:

  • ASD Healthcare*
    Order Number: 50514
    1-800-746-6273
  • Cardinal Health*
    Order Number: 0542169
    1-866-677-4844
  • McKesson Plasma & Biologics*
    Order Number: 3758315
    1-877-625-2566
  • Morris & Dickson
    Order Number: 248377
    1-800-388-3833

* Consignment programs are available. Please ask your specialty distributor.

 

Indication GIAPREZA increases blood pressure in adults with septic or other distributive shock.
Contraindications None.
NDC NDC 68547-501-02 (1 carton of one 1 mL single-dose vial containing 2.5 mg angiotensin II).
How supplied GIAPREZA injection is a clear, aqueous solution for administration by intravenous infusion supplied as a single-dose vial.
Dimensions 3 in × 1.25 in × 1.25 in.
Storage GIAPREZA vials should be stored in the refrigerator (36-46°F, 2-8°C).
Diluted solution may be stored at room temperature or under refrigeration.
Discard prepared diluted solution after 24 hours at room temperature or under refrigeration.

Get the ordering information sheet

Download Now

Important Safety Information See more

Warnings and Precautions The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the randomized, double-blind, placebo-controlled ATHOS-3 study. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism prophylaxis.

IndicationGIAPREZA™ (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

Important Safety Information

Indication GIAPREZA™ (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

Contraindications None.

Warnings and Precautions The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the randomized, double-blind, placebo-controlled ATHOS-3 study. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism prophylaxis.

Adverse Reactions The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.

Drug Interactions Angiotensin converting enzyme inhibitors may increase response to GIAPREZA.

Angiotensin II receptor blockers may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional Important Safety Information, please see the full Prescribing Information.

Reference: GIAPREZA™ (angiotensin II) [prescribing information]. San Diego, CA: La Jolla Pharmaceutical Company; 2017.